Quick Summary:
In the dynamic pharmaceutical landscape, the global market for EGFRm-positive NSCLC is an area of expanding opportunities and significant breakthroughs. Executives in the healthcare and pharmaceutical sectors would gain an unparalleled advantage by accessing our comprehensive market research report, which delves deeply into the progression of the industry and its future growth trajectory.
Our meticulously prepared report serves as a vital tool in strategic planning, offering a thorough analysis of regional supply chains, demand trends, and the competitive landscape, with a spotlight on key players and emergent market entrants. By integrating SWOT analyses, business information, and market share data into your decision-making processes, you can skillfully navigate the market and capitalize on growth prospects.
For the geography segment, regional supply, demand, major players, price is presented from 2019 to 2029. This report cover following regions:
- North America
- South America
- Asia & Pacific
- Europe
- MEA
For the competitor segment, the report includes global key players of EGFRm-positive NSCLC as well as some small players. The information for each competitor include:
- Company Profile
- Business Information
- SWOT Analysis
- Revenue, Gross Margin and Market Share
Types Segment:
- Afatinib
- Amivantamab
- Dacomitinib
- Others
Companies Covered:
- AstraZeneca
- Johnson & Johnson
- Takeda Pharmaceutical
- Blueprint Medicines Corp
- Dizal Pharmaceutical
- Oric Pharmaceuticals
- etc.
Historical Data: from 2019 to 2023
Forecast Data: from 2024 to 2029
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- AstraZeneca
- Johnson & Johnson
- Takeda Pharmaceutical
- Blueprint Medicines Corp
- Dizal Pharmaceutical
- Oric Pharmaceuticals
- Black Diamond Therapeutics Inc.
- Taiho Pharmaceutical Co. Ltd.
- Boehringer Ingelheim
- Bayer AG
- ArriVent Biopharma
Methodology
LOADING...